Tumor Treating Fields (TTFields) are low intensity alternating electric fields, which are tuned to interfere with the division process of cancer cells [Science of TTFields]. TTFields are delivered to the body region where the tumor is located using an investigational medical device, called the NovoTTF-100L System. The system is a portable, light-weighted, battery operated device designed to deliver TTFields to the non-small cell lung cancer (NSCLC). Patients receiving TTFields need to wear four transducer arrays on their chest, which deliver the fields non-invasively to the lungs. The system is intended for continuous home use by patients [Living with TTFields].

The NovoTTF 100L System is not FDA approved to treat non-small cell lung cancer. Therefore, the safety and efficacy of TTFields in this condition is still unknown, and will be evaluated in this clinical trial [The LUNAR Trial].

TTFields have been approved by the FDA for treatment of adult patients suffering from recurrent and newly diagnosed glioblastoma.